Piroxicam betadex

Drug Profile

Piroxicam betadex

Alternative Names: Beta-cyclodextrin piroxicam; Brexecam; Brexidol; Brexin; Brexine; Brexinil; CHF 1194; Cicladol; Cycladol; Flogene; Piroxicam beta-cyclodextrin; Piroxicam beta-cyclodextrin complex; Solocalm Rapido

Latest Information Update: 16 Mar 2015

Price : $50

At a glance

  • Originator Chiesi
  • Class Antirheumatics; Beta-Cyclodextrins; Carbohydrates; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Dysmenorrhoea; Gout; Inflammation; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatic disorders; Rheumatoid arthritis
  • No development reported Migraine; Tension type headache

Most Recent Events

  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 23 Aug 2001 Schwarz Pharma has terminated its licensing agreement for the agent in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top